Health
FDA says Paxlovid is not linked to COVID-19 rebound
As the U.S. Food and Drug Administration’s independent advisers prepare to discuss the full approval of Pfizer’s COVID-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults.
Top Stories
Just the News Spotlight
Just News, No Noise
Trending
- Leftist coalition wins most seats but no party wins majority in French election; turmoil projected
- Comer takes aim at White House physician, seeks answers over alleged help to Biden family businesses
- European leaders customarily mum on US presidential elections, candidates, but Biden's changing that
- Elon Musk embraces noncitizen voting ban, suggest opponents of proposed law are ‘traitors’
- Follow science? Duke dumped doc who exposed lack of evidence for 'racism is a public health crisis'